The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate

Yonsei University

Status: Completed

Conditions: Transurethral Prostatectomy

Treatments: Drug: Dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT01224470

4-2010-0405

Details and patient eligibility

About

Dexmedetomidine is a new selective and potent alpha-2 agonist. It has centrally acting anesthetic properties. It has been known that intrathecal addition of alpha-2 adrenergic agents result in prolongation of the duration of the sensory and motor blockade induced by hyperbaric bupivacaine. But the effects of intravenous dexmedetomidine on the spinal block was not evaluated. The aim of study is to assess the effect of intravenous dexmedetomidine on the low-dose spinal anesthesia for the transurethral surgery.

Enrollment: 51 patients

Sex: Male

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ASA class I or II
• Elective transurethral prostatectomy
• aged > 20

Exclusion criteria

• Coagulation deficiency
• infection on the back
• Congestive heart failure or arrythmia
• Chronic alcoholic disease
• Antidepressants therapy

Trial design

51 participants in 2 patient groups, including a placebo group

bupivacaine

Active Comparator group

Description:

0.5% bupivacaine 1.2 mL + normal saline 0.8 mL = total 2 mL

Treatment:

Drug: Dexmedetomidine

saline

Placebo Comparator group

Treatment:

Drug: Dexmedetomidine